U.S. Markets open in 4 hrs 8 mins

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.07-0.09 (-0.18%)
At close: 4:02PM EDT
People also watch
NVSGSKAZNLLYNVO
Interactive chart
Previous Close49.16
Open49.32
Bid0.00 x
Ask0.00 x
Day's Range48.99 - 49.41
52 Week Range36.81 - 50.24
Volume1,835,591
Avg. Volume1,662,495
Market Cap116.97B
Beta0.75
PE Ratio (TTM)24.77
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.21%)
Ex-Dividend Date2017-05-11
1y Target EstN/A
Trade prices are not sourced from all markets
  • Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis
    Investor's Business Daily13 hours ago

    Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis

    Regeneron and Sanofi's rheumatoid arthritis drug is 15%-30% cheaper than rival drugs from Amgen, AbbVie and Roche, an analyst said Tuesday.

  • American City Business Journals14 hours ago

    ​Sanofi Genzyme takes on world’s top-selling drugs with new approval

    With Monday’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for that same disease: give it a lower price. Cambridge-based Sanofi Genzyme (SNY) and Tarrytown, N.Y.-based Regeneron (REGN) will market their new drug, which has the generic name of sarilumab, under the name of Kevzara. Rheumatoid arthritis affects about 1.3 million Americans, mostly women, and Kevzara is approved for those with moderate to severe forms of the disease that aren’t well treated by other drugs.

  • Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
    Zacks19 hours ago

    Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis

    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.